Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study maps bladder cancer in latin america

NCT ID NCT03942497

Knowledge-focused Sponsor: Latin American Cooperative Oncology Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 218 patients with advanced bladder cancer in Latin America. Researchers collected information on patient backgrounds, treatments, and survival. The goal was to better understand the disease in this region, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

218 people

The number who actually took part.

Started

Aug 2019

Finished

Feb 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with recurrent/ metastatic urothelial carcinoma diagnosed between January 2016 to July 2018.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age at least 18 years; 2. Histological confirmation of urothelial carcinoma (include mixed urothelial histology); 3. Diagnosis of recurrent or metastatic (Stage IV) urothelial carcinoma during the period of January 2016 to July 2018; 4. Site and investigator ability to collect adequate patient characteristics, treatment and outcome data from medical records; 5. Availability of tumor sample (FFPE/slides) from primary tumor or metastatic site at the time of registration. Exclusion Criteria: 1. Synchronous tumors or history of other malignancy in the previous 3 years before study entry (exception to non-melanoma skin cancer or non-invasive cancers); 2. Pure non-urothelial carcinoma histology.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Recurrent/metastatic urothelial cancers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Neoplasm Metastasis Recurrence urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Recurrent/metastatic urothelial cancers

Contacts and locations

Locations

  • Beneficência Portuguesa

    São Paulo, São Paulo, Brazil

  • CEPON

    Florianópolis, Santa Catarina, Brazil

  • CLION

    Salvador, Estado de Bahia, Brazil

  • CPO Pucrs

    Porto Alegre, Rio Grande do Sul, Brazil

  • Centro Paulista de Oncologia

    São Paulo, São Paulo, Brazil

  • Clínica AMO

    Salvador, Estado de Bahia, Brazil

  • Hospital São Rafael

    Salvador, Estado de Bahia, Brazil

  • LIGA

    Curitiba, Paraná, Brazil

  • Sírio Libanês

    São Paulo, São Paulo, Brazil